Royalty Report: Drugs, Disease, Diabetes Treatment – Collection: 209493


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Disease
  • Diabetes Treatment
  • Delivery
  • Therapeutic
  • Biotechnology
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 209493

License Grant
In consideration of Licensors performance, to date, under the Agreement and its agreement herein to relinquish all of its rights in and to the Licensee Products.
License Property
The rights relate to the sale of Metformin in the United States.  Metformin is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight.
Field of Use
This agreement is for the pharmaceutical industry.

Metformin is used in the treatment of diabetes.

IPSCIO Record ID: 26162

License Grant
Pursuant to the development and license agreement, licensee has an exclusive, worldwide license to the technology for the development and commercialization of injectable extended-release formulations of exendins and other related compounds.
License Property
Two U.S. pharmaceutical companies are collaborating on the development of exenatide once weekly for the treatment of type 2 diabetes. Exenatide once weekly is an injectable formulation of Licensee’s Byetta® (exenatide). Byetta is an injection administered twice daily. Diabetes is a disease in which the body does not produce or properly use insulin. Diabetes can result in serious health complications, including cardiovascular, kidney and nerve disease. Byetta was approved by the FDA in April 2005 as adjunctive therapy to improve blood sugar control in patients with type 2 diabetes who have not achieved adequate control on metformin and/or a sulfonylurea, which are commonly used oral diabetes medications. In December 2006, the FDA approved Byetta as an add-on therapy for people with type 2 diabetes unable to achieve adequate glucose control on thiazolidinediones, a class of diabetes medications. Licensee has an agreement with another pharmaceutical company for the development and commercialization of exenatide, including exenatide once weekly. Exenatide once weekly is being developed with the goal of providing patients with an effective and more patient-friendly treatment option.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 123563

License Grant
The Licensor granted the Licensee an exclusive, worldwide, royalty-bearing right and license under its patent rights and know-how to develop, manufacture and commercialize sotagliflozin.
License Property
The IP Property is the Licensors diabetes drug candidate sotagliflozin or LX4211, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes.
Field of Use
The Licensee will be responsible for all clinical development and commercialization of sotagliflozin for the treatment of type 2 diabetes worldwide and will be solely responsible for the commercialization of sotagliflozin for the treatment of type 1 diabetes outside the United States.

IPSCIO Record ID: 275800

License Grant
Licensor grants to Licensee of Barbados an exclusive license in the Territory under the Patent Rights, Know-How and Technical Information, with the right, to grant sublicenses of the same scope as the license granted by this Agreement, or to appoint a Distributor, to Manufacture and Market 500mg Product in, and import 500mg Product into, the Territory.

Licensor grants to Licensee of Barbados a non-exclusive license under the Foreign Patent Rights, Know-How and Technical Information, with the right, to grant sublicenses of the same scope as the license granted, to Manufacture 500mg Product in the United States or Puerto Rico for export to the Territory for sale in the Territory in compliance with this Agreement.

License Property
The Active Ingredient shall mean the chemical compound known as metformin HCl.

The 500mg Product shall mean the once-daily oral formulation of the Active Ingredient in combination with the AcuForm Delivery Technology.

The 1000mg Product shall mean the once daily oral tablet formulation of the Active Ingredient in a 1000 mg strength to be developed using proprietary Licensee drug delivery technology pursuant to the Supply Agreement.

Invention shall mean the 500mg Product, any improvement to the 500mg Product, any new use of the 500mg Product, any new performance characteristic of the 500mg Product, any new process used to Manufacture the 500mg Product, or any step or steps in any such process, and includes all formulations of the 500mg Product developed pursuant to the Prior Agreement.

The patents are titles:  Extending the Duration of Drug Release Within the Stomach During the Fed Mode; Gastric-Retentive, Oral Drug Dosage Forms for the Controlled Release of Sparingly Soluble Drugs and Insoluble Matter;  Alkyl-Substituted Cellulose-Based Sustained Release Oral Drug Dosage Forms;  and, Sustained-release oral drug dosage form.

Field of Use
The field of use for the metformin product is Type II diabetes.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.